IN2014MN01879A - - Google Patents
Info
- Publication number
- IN2014MN01879A IN2014MN01879A IN1879MUN2014A IN2014MN01879A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A IN 1879MUN2014 A IN1879MUN2014 A IN 1879MUN2014A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- antibody chains
- derivatives
- chimaeric
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/433,084 US9445581B2 (en) | 2012-03-28 | 2012-03-28 | Animal models and therapeutic molecules |
US13/434,361 US9253965B2 (en) | 2012-03-28 | 2012-03-29 | Animal models and therapeutic molecules |
PCT/GB2013/050682 WO2013144566A2 (en) | 2012-03-28 | 2013-03-18 | Animal models and therapeutic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01879A true IN2014MN01879A (tr) | 2015-07-03 |
Family
ID=47913490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1879MUN2014 IN2014MN01879A (tr) | 2012-03-28 | 2013-03-18 |
Country Status (12)
Country | Link |
---|---|
US (7) | US9253965B2 (tr) |
EP (3) | EP2785845A2 (tr) |
JP (4) | JP6336435B2 (tr) |
CN (1) | CN104334732B (tr) |
AU (1) | AU2013239501B2 (tr) |
CA (1) | CA2867530A1 (tr) |
DK (1) | DK2831244T3 (tr) |
HK (1) | HK1200872A1 (tr) |
IN (1) | IN2014MN01879A (tr) |
NZ (1) | NZ629202A (tr) |
SG (1) | SG11201405058WA (tr) |
WO (2) | WO2013061098A2 (tr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174053A1 (en) | 2006-09-01 | 2011-09-29 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
DK3028565T3 (da) | 2009-07-08 | 2017-11-13 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
RU2580017C2 (ru) | 2010-07-26 | 2016-04-10 | Трианни, Инк. | Трансгенные животные и способы применения |
MX2018014787A (es) | 2010-08-02 | 2023-02-14 | Regeneron Pharma | Ratones que producen proteinas de union que comprenden dominios vl. |
PL2738258T5 (pl) | 2011-02-25 | 2023-05-15 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
EP4091442A1 (en) | 2011-09-19 | 2022-11-23 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
WO2013059230A1 (en) | 2011-10-17 | 2013-04-25 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
JP6327750B2 (ja) | 2011-12-20 | 2018-05-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化軽鎖マウス |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
KR20240042174A (ko) | 2012-06-12 | 2024-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
SG11201505383UA (en) | 2013-02-20 | 2015-08-28 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
SG11201602236SA (en) * | 2013-10-01 | 2016-04-28 | Kymab Ltd | Animal models and therapeutic molecules |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP6636498B2 (ja) | 2014-03-21 | 2020-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 単一ドメイン結合タンパク質を作る非ヒト動物 |
EP3119811B1 (en) | 2014-03-21 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
IL278350B (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
ES2874558T3 (es) | 2015-03-04 | 2021-11-05 | Igm Biosciences Inc | Moléculas de unión a CD20 y usos de las mismas |
JP2018508224A (ja) | 2015-03-19 | 2018-03-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗原を結合する軽鎖可変領域を選択する非ヒト動物 |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
WO2017132376A1 (en) | 2016-01-27 | 2017-08-03 | Just Biotherapeutics, Inc. | Hybrid promoter and uses thereof |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
KR20180104149A (ko) | 2016-02-04 | 2018-09-19 | 트리아니, 인코포레이티드 | 면역글로불린의 증대된 생성 |
GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
WO2017220988A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Multispecific antibodies for immuno-oncology |
KR20230044038A (ko) | 2016-08-09 | 2023-03-31 | 키맵 리미티드 | 항-icos 항체 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
WO2018144097A1 (en) | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
RS60886B1 (sr) | 2016-11-04 | 2020-11-30 | Regeneron Pharma | Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca |
CA3045323A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
AU2018302668A1 (en) * | 2017-07-21 | 2020-02-06 | I'rom Group Co., Ltd. | Polynucleotide for modifying target sequence and use thereof |
WO2019037099A1 (en) * | 2017-08-25 | 2019-02-28 | Wenning Qin | LARGE SCALE MODIFICATION OF GENOME EUCARYOTE |
PL3720279T3 (pl) * | 2017-12-05 | 2023-01-16 | Regeneron Pharmaceuticals, Inc. | Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
CN108486126A (zh) * | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在人源化抗体中的应用 |
GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
CN117099741A (zh) | 2019-02-18 | 2023-11-24 | 百奥赛图(北京)医药科技股份有限公司 | 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物 |
BR112021019128A2 (pt) | 2019-04-09 | 2022-01-04 | Abcuro Inc | Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1) |
WO2021003149A1 (en) * | 2019-07-01 | 2021-01-07 | Trianni, Inc. | Transgenic mammals and methods of use |
BR112022010424A2 (pt) | 2019-11-29 | 2022-08-23 | Kymab Ltd | Tratamento para sobrecarga de ferro fisiológica |
KR20230024822A (ko) | 2020-06-25 | 2023-02-21 | 주식회사 휴맵 | 이형접합성 형질전환 동물 |
WO2022026775A1 (en) * | 2020-07-30 | 2022-02-03 | Prellis Biologics, Inc | Compositions and methods for targeting coronavirus |
JP2023540808A (ja) | 2020-09-11 | 2023-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗原特異的抗体の同定及び産生 |
CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
WO2023009498A1 (en) | 2021-07-26 | 2023-02-02 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US4720449A (en) | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5859307A (en) | 1992-02-04 | 1999-01-12 | Massachusetts Institute Of Technology | Mutant RAG-1 deficient animals having no mature B and T lymphocytes |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
JP4242447B2 (ja) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Cd40リガンド遺伝子の突然変異の検出および治療 |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE4331162A1 (de) | 1993-09-14 | 1995-03-16 | Bayer Ag | Verfahren zur Herstellung von Cyaninfarbstoffen |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
WO1997049804A1 (en) | 1996-06-26 | 1997-12-31 | Baylor College Of Medicine | Chromosomal rearrangement by insertion of two recombination substrates |
ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
ES2245487T3 (es) | 1997-11-18 | 2006-01-01 | Pioneer Hi-Bred International, Inc. | Composiciones y metodos para la modificacion genetica de plantas. |
AU752105B2 (en) | 1997-12-05 | 2002-09-05 | Europaisches Laboratorium Fur Molekularbiologie (Embl) | Novel dna cloning method |
EP0939120A1 (en) | 1998-02-27 | 1999-09-01 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells |
GB9823930D0 (en) * | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US6355412B1 (en) | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2307503A1 (en) | 2000-05-02 | 2001-11-02 | Carlos F. Barbas Iii | Peptides for use as a vaccine or treatment for hiv infection |
CN1455817A (zh) | 2000-07-21 | 2003-11-12 | (由农业部部长代表的)美利坚合众国 | 用于在真核基因组中置换、转移和富积dna的方法 |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP2042594B1 (en) | 2000-11-17 | 2011-03-23 | Kyowa Hakko Kirin Co., Ltd. | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
NZ569856A (en) | 2001-01-05 | 2010-03-26 | Pfizer | Antibodies to insulin-like growth factor 1 receptor |
FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
ES2645563T3 (es) * | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
US20050095712A1 (en) | 2002-01-17 | 2005-05-05 | Alberto Martin | Mutations caused by activation-induced cytidine deaminase |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
WO2004022738A1 (en) | 2002-09-09 | 2004-03-18 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
DE10251918A1 (de) | 2002-11-08 | 2004-05-19 | Horn, Carsten, Dipl.-Biochem. Dr. | Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen |
US7700356B2 (en) | 2002-11-08 | 2010-04-20 | The United States Of America As Represented By The Secretary Of Agriculture | System for gene targeting and producing stable genomic transgene insertions |
AR042145A1 (es) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2005001087A2 (en) | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
GB2403475B (en) | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
JP2005042792A (ja) | 2003-07-28 | 2005-02-17 | Nsk Ltd | ローラクラッチ及びローラクラッチ内蔵型プーリ装置 |
US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
US7604994B2 (en) | 2003-09-03 | 2009-10-20 | Morphotek, Inc. | Genetically altered antibody-producing cell lines with improved antibody characteristics |
CA2445602C (en) | 2003-10-20 | 2014-01-14 | Campusgen Gmbh | Nucleotide sequence for creatinine deiminase and method of use |
DK1691837T3 (da) | 2003-12-10 | 2012-10-01 | Medarex Inc | IP-10-antistoffer og anvendelse heraf |
AU2005227313A1 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through V gene manipulation |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
BRPI0513577A (pt) | 2004-07-22 | 2008-05-06 | Univ Erasmus Medical Ct | moléculas ligantes |
FR2875239B1 (fr) | 2004-09-10 | 2007-07-20 | Inst Necker Ass Loi De 1901 | Procede pour l'acceleration des mutations somatiques et son application en proteomique |
WO2006044492A2 (en) | 2004-10-14 | 2006-04-27 | Ingenious Targeting Laboratory, Inc. | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome |
AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
WO2006055704A2 (en) | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
CA2608481A1 (en) | 2005-05-14 | 2006-11-23 | Fudan University | Piggybac as a tool for genetic manipulation and analysis in vertebrates |
EP1780272A1 (en) | 2005-10-27 | 2007-05-02 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Method for enhancing somatic hypermutation, gene conversion and class switch recombination |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
EP2043695B8 (en) | 2006-06-27 | 2012-02-29 | Sanofi Pasteur VaxDesign Corporation | Models for vaccine assessment |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
CN101501073A (zh) | 2006-08-22 | 2009-08-05 | G2英弗勒美欣私人有限公司 | 抗体制备方法 |
HUE054090T2 (hu) | 2006-10-02 | 2021-08-30 | Regeneron Pharma | A humán IL-4 receptorral szemben nagy affinitást mutató humán antitestek |
US7732195B2 (en) | 2006-11-01 | 2010-06-08 | Facet Biotech Corporation | Tethered vectors for cell surface immunoglobulin display |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
JP5779350B2 (ja) | 2007-03-27 | 2015-09-16 | シー レーン バイオテクノロジーズ, エルエルシー | 抗体代替軽鎖配列を含む構築物およびライブラリー |
GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
PL2336329T3 (pl) | 2007-06-01 | 2013-04-30 | Omt Inc | Kompozycje i sposoby hamowania endogennych genów immunoglobulin i wytwarzanie transgenicznych ludzkich idiotypowych przeciwciał |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
AU2008282152B2 (en) | 2007-07-31 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
EP2572729A3 (en) | 2007-08-10 | 2013-06-05 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
WO2009097006A2 (en) | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
JP2009122383A (ja) * | 2007-11-14 | 2009-06-04 | Canon Inc | 揺動体装置の製造方法、該製造方法により製造された揺動体装置によって構成される光偏向器及び光学機器 |
KR20100103810A (ko) | 2007-12-10 | 2010-09-28 | 알리바 바이오파마수티컬스, 아이엔씨. | 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법 |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
CN101978000A (zh) | 2008-01-25 | 2011-02-16 | 卡伯特公司 | 制备改性有色颜料的方法 |
KR101409375B1 (ko) | 2008-01-31 | 2014-06-18 | 삼성전자주식회사 | 반도체 메모리장치의 블록 디코딩 회로 |
WO2009118524A2 (en) | 2008-03-26 | 2009-10-01 | Iti Scotland Limited | Efficient insertion of dna into embryonic stem cells |
EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
EP2288623B1 (en) | 2008-05-23 | 2013-07-10 | Ablexis, LLC | Method of generating single vl domain antibodies in transgenic animals |
PL2147594T3 (pl) | 2008-06-27 | 2014-04-30 | Merus Nv | Wytwarzające przeciwciała ssaki inne niż człowiek |
EP3889265A1 (en) | 2008-09-30 | 2021-10-06 | Ablexis, LLC | Transgenic mice for the production of chimeric antibodies |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CN112690250B (zh) | 2008-12-18 | 2024-03-08 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
WO2010091182A2 (en) | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
JP2012518398A (ja) | 2009-02-24 | 2012-08-16 | グラクソ グループ リミテッド | 抗原結合性構築物 |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
CN102482639B (zh) | 2009-04-03 | 2016-01-06 | 医学研究会 | 活化诱导胞苷脱氨酶(aid)突变体及使用方法 |
JP2012531208A (ja) | 2009-06-26 | 2012-12-10 | シー レーン バイオテクノロジーズ, エルエルシー | 代替軽鎖の発現 |
DK3028565T3 (da) | 2009-07-08 | 2017-11-13 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
WO2011008093A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US8592644B2 (en) | 2009-08-13 | 2013-11-26 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal CDRS |
EP2496706A4 (en) | 2009-11-05 | 2013-07-17 | Anaptysbio Inc | PROCESS FOR PREPARING IMPROVED ANTIGEN BINDING OF THE CHAIN FORMING AND OPTIONAL SOMATIC HYPERMUTATION |
CA2781159A1 (en) | 2009-11-17 | 2011-05-26 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome vector |
EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
KR101553244B1 (ko) | 2009-12-10 | 2015-09-15 | 리제너론 파마슈티칼스 인코포레이티드 | 중쇄 항체를 만드는 마우스 |
ES2603559T5 (es) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Cadena ligera común de ratón |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
NZ605966A (en) | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
PL3034608T3 (pl) | 2010-06-22 | 2019-08-30 | Regeneron Pharmaceuticals, Inc. | Myszy wykazujące ekspresję hybrydowego łańcucha lekkiego immunoglobuliny z ludzkim regionem zmiennym |
MX2018014787A (es) | 2010-08-02 | 2023-02-14 | Regeneron Pharma | Ratones que producen proteinas de union que comprenden dominios vl. |
RU2608640C2 (ru) | 2010-08-16 | 2017-01-23 | Новиммун С.А. | Способы получения мультиспецифичных и мультивалентных антител |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
WO2012088313A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
PL2738258T5 (pl) | 2011-02-25 | 2023-05-15 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
ES2872081T3 (es) | 2011-08-05 | 2021-11-02 | Regeneron Pharma | Ratones con cadena ligera universal humanizada |
EP4091442A1 (en) | 2011-09-19 | 2022-11-23 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
JP2014531452A (ja) | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
WO2013059230A1 (en) | 2011-10-17 | 2013-04-25 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US20130102031A1 (en) | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
JP6327750B2 (ja) | 2011-12-20 | 2018-05-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化軽鎖マウス |
SG10201606256TA (en) | 2012-02-01 | 2016-09-29 | Regeneron Pharma | Humanized rodents that express heavy chains containing vl domains |
CN108101983A (zh) | 2012-03-02 | 2018-06-01 | 瑞泽恩制药公司 | 艰难梭状芽孢杆菌毒素的人源抗体 |
JP2015509380A (ja) | 2012-03-06 | 2015-03-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖のマウス |
CA2865644A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
LT2800811T (lt) | 2012-05-25 | 2017-09-11 | The Regents Of The University Of California | Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr |
KR20240042174A (ko) | 2012-06-12 | 2024-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
SG11201505383UA (en) | 2013-02-20 | 2015-08-28 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US20150033372A1 (en) | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US20140331344A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Ltd. | Transgenic Animals |
US20140331339A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Limited | Transgenic Non-Human Assay Vertebrates, Assays and Kits |
SG11201602236SA (en) | 2013-10-01 | 2016-04-28 | Kymab Ltd | Animal models and therapeutic molecules |
-
2012
- 2012-03-29 US US13/434,361 patent/US9253965B2/en active Active
- 2012-11-30 EP EP12795841.1A patent/EP2785845A2/en not_active Withdrawn
- 2012-11-30 WO PCT/GB2012/052960 patent/WO2013061098A2/en active Application Filing
-
2013
- 2013-03-18 DK DK13711119.1T patent/DK2831244T3/en active
- 2013-03-18 WO PCT/GB2013/050682 patent/WO2013144566A2/en active Application Filing
- 2013-03-18 EP EP18153171.6A patent/EP3366126B1/en active Active
- 2013-03-18 CN CN201380027944.1A patent/CN104334732B/zh active Active
- 2013-03-18 EP EP13711119.1A patent/EP2831244B1/en active Active
- 2013-03-18 NZ NZ629202A patent/NZ629202A/en not_active IP Right Cessation
- 2013-03-18 CA CA2867530A patent/CA2867530A1/en not_active Abandoned
- 2013-03-18 JP JP2015502439A patent/JP6336435B2/ja active Active
- 2013-03-18 IN IN1879MUN2014 patent/IN2014MN01879A/en unknown
- 2013-03-18 SG SG11201405058WA patent/SG11201405058WA/en unknown
- 2013-03-18 AU AU2013239501A patent/AU2013239501B2/en not_active Expired - Fee Related
-
2015
- 2015-02-06 HK HK15101357.8A patent/HK1200872A1/xx unknown
-
2016
- 2016-02-08 US US15/018,670 patent/US9924705B2/en active Active
- 2016-12-19 US US15/383,202 patent/US9938358B2/en active Active
- 2016-12-19 US US15/383,196 patent/US9938357B2/en active Active
-
2018
- 2018-04-09 US US15/948,709 patent/US10774155B2/en active Active
- 2018-05-02 JP JP2018088749A patent/JP2018119012A/ja active Pending
-
2020
- 2020-07-30 JP JP2020129123A patent/JP2020176140A/ja active Pending
- 2020-09-15 US US17/020,997 patent/US20210079118A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/947,884 patent/US20230159660A1/en active Pending
- 2022-11-04 JP JP2022177513A patent/JP7475415B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01879A (tr) | ||
AU2023200884B2 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
WO2015049517A3 (en) | Animal models and therapeutic molecules | |
HK1162119A1 (en) | Animal models and therapeutic molecules | |
CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
EP2604110A3 (en) | Animal models and therapeutic molecules | |
MY178142A (en) | Anti-phf-tau antibodies and their uses | |
EA201790664A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
EP4324480A3 (en) | Anti-transferrin receptor antibodies and methods of use | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
IN2014MN01642A (tr) | ||
EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
MX2014004326A (es) | Anticuerpos a cd1d. | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. |